RALLYBIO CORPORATION APIC, Share-based Payment Arrangement, Increase for Cost Recognition
RALLYBIO CORPORATION (RLYB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $424.00 thousand for the 3-month period ending 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-26
- RALLYBIO CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $424.00K, a 73.73% decline year-over-year.
- RALLYBIO CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $613.00K, a 67.38% decline year-over-year.
- RALLYBIO CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $774.00K, a 60.57% decline year-over-year.
- RALLYBIO CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.05M, a 48.35% decline year-over-year.
- RALLYBIO CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $10.92M, a 14.96% increase from fiscal 2022.
- RALLYBIO CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $9.50M, a 160.60% increase from fiscal 2021.
- RALLYBIO CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $3.65M, a 417.76% increase from fiscal 2020.
- RALLYBIO CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $704.00K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $424.00K S-4/A · filed 2026-08-26 | $1.04M S-4/A · filed 2026-08-26 | $1.81M derived: sum of 3 quarters · filed 2026-08-26 | $2.86M derived: sum of 4 quarters · filed 2026-08-26 |
| 2026-03-31 | $613.00K S-4 · filed 2026-07-15 | $1.39M derived: sum of 2 quarters · filed 2026-08-26 | $2.43M derived: sum of 3 quarters · filed 2026-08-26 | $4.05M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-12-31 | $774.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $1.82M derived: sum of 2 quarters · filed 2026-08-26 | $3.44M derived: sum of 3 quarters · filed 2026-08-26 | $5.31M S-4/A · filed 2026-08-26 |
| 2025-09-30 | $1.05M 10-Q · filed 2025-11-06 | $2.66M derived: sum of 2 quarters · filed 2026-08-26 | $4.54M 10-Q · filed 2025-11-06 | $6.50M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-06-30 | $1.61M S-4/A · filed 2026-08-26 | $3.49M S-4/A · filed 2026-08-26 | $5.46M derived: sum of 3 quarters · filed 2026-08-26 | $7.48M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-03-31 | $1.88M S-4 · filed 2026-07-15 | $3.84M derived: sum of 2 quarters · filed 2026-08-26 | $5.87M derived: sum of 3 quarters · filed 2026-08-26 | $7.78M derived: sum of 4 quarters · filed 2026-08-26 |
| 2024-12-31 | $1.96M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $3.99M derived: sum of 2 quarters · filed 2026-08-26 | $5.91M derived: sum of 3 quarters · filed 2026-08-26 | $7.99M S-4/A · filed 2026-08-26 |
| 2024-09-30 | $2.03M 10-Q · filed 2025-11-06 | $3.94M derived: sum of 2 quarters · filed 2025-11-06 | $6.03M 10-Q · filed 2025-11-06 | $8.58M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.92M 10-Q · filed 2025-08-07 | $4.00M 10-Q · filed 2025-08-07 | $6.55M derived: sum of 3 quarters · filed 2025-08-07 | $9.19M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $2.09M 10-Q · filed 2025-05-08 | $4.64M derived: sum of 2 quarters · filed 2025-05-08 | $7.27M derived: sum of 3 quarters · filed 2025-05-08 | $9.96M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $2.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $5.18M derived: sum of 2 quarters · filed 2025-03-13 | $7.88M derived: sum of 3 quarters · filed 2025-03-13 | $10.92M 10-K · filed 2025-03-13 |
| 2023-09-30 | $2.63M 10-Q · filed 2024-11-07 | $5.33M derived: sum of 2 quarters · filed 2024-11-07 | $8.37M 10-Q · filed 2024-11-07 | $10.66M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $2.69M 10-Q · filed 2024-08-08 | $5.74M 10-Q · filed 2024-08-08 | $8.03M derived: sum of 3 quarters · filed 2024-08-08 | $10.54M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $3.04M 10-Q · filed 2024-05-09 | $5.34M derived: sum of 2 quarters · filed 2024-05-09 | $7.84M derived: sum of 3 quarters · filed 2024-05-09 | $10.49M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $4.80M derived: sum of 2 quarters · filed 2024-03-12 | $7.45M derived: sum of 3 quarters · filed 2024-03-12 | $9.50M 10-K · filed 2024-03-12 |
| 2022-09-30 | $2.50M 10-Q · filed 2023-11-09 | $5.15M derived: sum of 2 quarters · filed 2023-11-09 | $7.21M 10-Q · filed 2023-11-09 | $8.73M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $2.65M 10-Q · filed 2023-08-08 | $4.70M 10-Q · filed 2023-08-08 | $6.23M derived: sum of 3 quarters · filed 2023-08-08 | $7.29M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $2.05M 10-Q · filed 2023-05-09 | $3.58M derived: sum of 2 quarters · filed 2023-05-09 | $4.64M derived: sum of 3 quarters · filed 2023-05-09 | $5.18M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $2.58M derived: sum of 2 quarters · filed 2023-03-06 | $3.12M derived: sum of 3 quarters · filed 2023-03-06 | $3.65M 10-K · filed 2023-03-06 |
| 2021-09-30 | $1.05M 10-Q · filed 2022-11-07 | $1.59M derived: sum of 2 quarters · filed 2022-11-07 | $2.12M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $539.00K 10-Q · filed 2022-08-08 | $1.06M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $522.00K 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $704.00K 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |